Corroborating with these reports, we showed that the mTOR inhibitor OSI-027, an orally available anti-cancer drug currently being evaluated in Phase I clinical trial for advanced solid malignancies [53], exhibited significant antiviral activity against both MERS-CoV and SARS-CoV-2. Here, MTOR is linked to cancer.